Floatz logo

PREDNISONE TABLETS

Oral Squamous Cell Carcinoma

MacroGenicsSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Oral Squamous Cell Carcinoma cohort.

Asset / SponsorPhaseRating
AEX4089DC1
MacroGenics
Phase 2CCC
Abiraterone Acetate
MacroGenics
Phase 2CCC
Enzalutamide
MacroGenics
Phase 2CCC
SX682
National Cancer Institute (NCI)
Phase 1/2CCC
Docetaxel
National Cancer Institute (NCI)
Phase 1/2CCC
Vobramitamab Duocarmazine
MacroGenics
Phase 2C

Same molecule, other indications

PREDNISONE TABLETS is also rated in:

Recurrent Adult T-cell Leukemia/LymphomaDormant
BBB
Indicative ·
76 / 100
View asset →
diffuse large B-cell lymphomaDormant
BBB
Indicative ·
74 / 100
View asset →
metastatic prostate carcinomaDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →